Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sigma Healthcare Ltd (ASX: SIG) shares are rocketing on Thursday morning.

At the time of writing, the pharmacy chain operator and distributor's shares are up 39% to $2.71.

This follows the release of an announcement relating to its plan to merge with Chemist Warehouse.

Sigma shares rocket on Chemist Warehouse news

Investors have been scrambling to buy the company's shares this morning after the Australian Competition & Consumer Commission (ACCC) revealed that it will not oppose the Sigma Healthcare and Chemist Warehouse merger after accepting a court-enforceable undertaking from the former.

Commenting on the decision, ACCC Chair Gina Cass-Gottlieb said.

The ACCC found that, with the undertaking, the proposed merger is unlikely to substantially lessen competition. There is and will continue to be effective competition at all levels of the pharmacy supply chain, capable of constraining a combined Sigma Chemist Warehouse.

The ACCC's analysis found that the proposed merger is unlikely to substantially lessen competition nationally or locally because other pharmacies and non-pharmacy retailers will continue to compete to the same extent they compete now.

Cass-Gottlieb also notes that consumers will still have plenty of choices even if the merger went ahead. She adds:

Consumers value different aspects of Sigma's and Chemist Warehouse's banner pharmacies' offerings. Importantly, consumers will continue to have choice between smaller format stores offering personalised services to consumers and the Chemist Warehouse offering, focussed on larger format discount stores and front-of-store offerings.

Sigma response

This news was well-received by Sigma Healthcare. This morning, it welcomed the decision by the ACCC.

Sigma's CEO and managing director, Vikesh Ramsunder, said:

The ACCC decision marks a critical milestone for the proposed transaction and provides us with the conviction to progress with the next steps in the process. The proposed transaction has the potential to create a leading ASX listed healthcare company through the combination of the complementary strengths of Sigma's state-of-the-art pharmaceutical distribution infrastructure with Chemist Warehouse Group's retailing know-how.

We believe the proposed merger will create a stronger business and accelerate our long-term growth ambitions, for the benefit of our stakeholders.

What now?

With ACCC approval granted, the company will now push ahead with its merger plans.

Management notes that Sigma is well-advanced in preparing the documentation shareholders require to vote on the proposed transaction.

However, this documentation must be reviewed by the relevant regulators before it is despatched to shareholders. This regulatory review is anticipated to occur this calendar year, and an update on transaction timing will be provided after that regulatory review.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Could CSL shares outperform the ASX 200 in 2026?

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Healthcare Shares

Why did CSL shares crash 39% in 2025?

Should you be buying the dip? Let's find out.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »